Life Around The Map

Let's Go Travel

Tempus Labs is a revolutionary creator of groundbreaking technology concerning cancer drugs and therapies. They use gene therapy and gene editing to help patients with diseases that were until previously untreatable. The company was founded less than five years ago by Eric Lefkofsky.

The results of Tempus’s labor has resulted in several of their products being FDA approved. Voretigeneneparvovec-rzyl, which is marketed at Luxturna, was approved by the US Food and Drug Administration right before the New Year. The drug was created to treat a rare form of vision loss that results from mutations of a certain gene.

Tempus, under the leadership of Lefkofsky also developed glucose sensors that can be used to directly dose insulin on a basis varying from person to person. The new discovery, which has also been FDA approved, is marketed as Abbot’s FreeStyleLibre Flash glucose monitor and is applied to the arm instead of requiring a person to prick their finger. The monitor can be set up to send data directly to a smartwatch or phone.

Who is Eric Lefkofsky?

Eric Lefkofsky is the co-founder and CEO of medical technology innovator Tempus. In 2006, he created the Lefkofsky Family Foundation, a charitable organization where he assists cancer patients in having a more fulfilling life. Lefkofsky graduated from the University of Michigan and the University of Michigan Law School. As well as being involved in advancement of medicine, he voyages in the worlds of art and theater. Other companies that Lefkofsky is involved in include, but are not limited to, Trustee of Luie Children’s Hospital of Chicago, The Art Institute of Chicago and Steppenwolrd Theatre Company.

Lefkofsky Family Foundation

The Lefkofsky Foundation was founded in 2006 by Eric Lefkofsky and his wife Liz with the purpose of advancing initiatives that relate to enhancing the lives of the community around them. The foundation primarily focuses medical research but also works to expand cultural initiatives in and around Chicago and is an advocate of human rights for women and young girls.

Eric Lefkofsky Info:

The world we live in today is increasingly becoming more tricky to navigate . We discover that the previously harmless diseases are now harmful. The cures we have for most of these diseases turn out to be making things worse. The dangers of globalized networks whose risks have chain reaction effects don’t also make things easier. One of the medical challenges of our time today is the one reported in Clay Siegall’s blog, and this challenge is the one about how children who suffer congenital heart disease will be facing new challenges in the future as adults.

As a form of the summary of the blog post, we can report here that according to an NPR report, the children who have defective congenital hearts will more likely suffer when they’re adults because of the complications that will finally resurface. This is in line with the concept of iatrogenics, which explains how the benefits we have right now will have their damages later on when we least expect them.

Clay Siegall’s blog also contains many other latest updates on what’s happening in our modern life. In fact, in another blog post, Mr. Clay wrote about how the NFL right now is scouting Lake Dawson for a potential GM job.

About Clay Siegall

Speaking of Clay Siegall, we should state here that Clay Siegall has built a name in being the CEO of Seattle Genetics. What does he do for a living? Simple. He makes the lives of many people better with the solutions and technological innovations that he’s led. With Seattle Genetics, which he co-founded and in which he is the president, he’s been able to grow an international company that right now has a NASDAQ stock market share.

Not for nothing is Clay Siegall known as one of today’s leading and successful business leaders. With his current economic success and his trademark measure of calm, it is little wonder why he’s one of the business leaders today worth emulating. It may even be accurate to say that his risk-taking skills are marked with intrepid, but skeptical optimism.

The more Seattle Genetics pushes for and promotes its programs, the more impressive does Clay become in the eyes of his investors and trustworthy clients.